HIMS Stock Recent News

Shares of Hims & Hers Health (HIMS 5.01%) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. That jump came as the S&P 500 and Nasdaq Composite showed more modest movements.

Hims & Hers Health is adding Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection liraglutide, to its platform. The company's GLP-1 offerings have evolved as the company has contended with a volatile supply and regulatory environment.

Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform. The post Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound appeared first on Investor's Business Daily.

Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform.

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $29.55, representing a +1.41% change from its previous close.

Hims & Hers (HIMS -8.84%) has seen incredibly high growth, but the market is skeptical that will continue. In this video, Travis Hoium shows just how cheap the stock is today.

What goes up can come down. Investors who jumped on the Hims & Hers Health (HIMS -4.12%) bandwagon have experienced this pain first-hand.

Hims & Hers stock price has imploded this year, erasing some of the gains made in 2024 when it became one of the top-performing companies in the US. HIMS has crashed to $33.35, down by over 54% from its highest point this year.

I think Hims & Hers Health has achieved "escape velocity", with a 95%+ increase year-over-year in Q4 2024 and expected 56%-63% growth in 2025, net of GLP-1 issues. The market overreacted to HIMS' stock drop, in my view. 2025 revenue guidance of $2.29-$2.39 billion and a 3.6x multiple on its $8.3 billion market cap suggest undervaluation. HIMS' PEG ratio of ~1 (P/E of 58 ÷ 56% growth) signals undervaluation for a high-growth company, typically seen in mature firms, not one scaling at 50%+ with 85% customer.

Hims & Hers Health, Inc. (HIMS) reachead $37.04 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.